Acumen Pharmaceuticals

ABOSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$176.235 M

$2.44 +7.02%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$121.3M

Loss-making

Shares outstanding

72,212,758

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#99Precision BiosciencesDTIL$193.3M
#100Outlook TherapeuticsOTLK$190.7M
#101Acumen PharmaceuticalsABOS$176.2M
#102Armata PharmaceuticalsARMP$172.9M
#103LENZ TherapeuticsLENZ$168.1M

Where these numbers come from

Share counts and financials for Acumen Pharmaceuticals are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.